To determine the in vivo effect of @entity1522 ( @entity4556 ) alone or in combination with insulin on splanchnic and muscle protein dynamics, we infused stable isotope tracers of @entity4556 in 36 healthy subjects and sampled from femoral artery and vein and hepatic vein. The subjects were randomized into six groups and were studied at baseline and during infusions of saline (group 1), insulin (0.5 mU. kg(-1). min(-1)) (group 2), insulin plus replacement of @entity4556 (group 3) insulin plus high-dose @entity4556 (group 4), or @entity1943 and baseline replacement doses of insulin, glucagon and GH plus high dose of @entity4556 (group 5) or saline (group 6). Insulin reduced muscle release of @entity4556 mainly by inhibition of protein breakdown. Insulin also enhanced AA-induced muscle protein synthesis (PS) and reduced @entity368 transamination. The main effect of @entity4556 on muscle was the enhancement of PS. Insulin had no effect on protein dynamics or @entity368 transamination in splanchnic bed. However, @entity4556 reduced protein breakdown and increased synthesis in splanchnic bed in a dose-dependent manner. @entity4556 also enhanced @entity368 transamination in both splanchnic and muscle beds. Thus insulin's anabolic effect was mostly on muscle, whereas @entity4556 acted on muscle as well as on splanchnic bed. Insulin achieved anabolic effect in muscle by inhibition of protein breakdown, enhancing AA-induced PS, and reducing @entity368 transamination. @entity4556 largely determined protein anabolism in splanchnic bed by stimulating PS and decreasing protein breakdown.

Differential regulation of protein dynamics in splanchnic and skeletal muscle beds by insulin and XXXX in healthy human subjects.

@entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin'] @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids'] @entity4556 :: ('CHEBI:73321', 'Chemical') :: ['AAs'] @entity368 :: ('CHEBI:25017', 'Chemical') :: ['leucine']
@entity1522 :: (CHEBI:33709,Chemical) :: ['amino acids']
